22 results
8-K
EX-99.1
SABS
SAB Biotherapeutics Inc
29 Mar 24
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
9:35am
also been deeply involved in the type 1 diabetes community for over 20 years, including as a volunteer and member of the Young
Leadership Committee
8-K
EX-99.1
SABS
SAB Biotherapeutics Inc
29 Nov 23
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying
7:40am
.
“For people living with T1D, the burden of disease is significant and there’s increasing focus – and need – within the research community to focus
425
SABS
SAB Biotherapeutics Inc
7 Sep 21
Business combination disclosure
10:36am
-of-concept and showed the FDA and the scientific community this could be a viable path to a drug, but then after the merger agreement was signed, Delta
8-K
SABS
SAB Biotherapeutics Inc
2 Oct 23
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
4:10pm
Chapter of the JDRF and was Chair of the Board of Trustees at the Great Neck Community School. Andrew received a B.A. in Economics, with distinction, from
424B3
SABS
SAB Biotherapeutics Inc
29 Apr 22
Prospectus supplement
4:16pm
of the Company’s potential products among physicians, patients, healthcare payers, and the medical community;
failure to successfully identify, develop … , healthcare payers, and the medical community;
we have received awards from the U.S. Government in multiple projects over the course of operations, including
POS AM
fhapyb6sn6
20 Apr 22
Prospectus update (post-effective amendment)
4:56pm
424B3
e4ijfgkepf4 uugdgwnp
29 Dec 21
Prospectus supplement
4:01pm
424B3
i5x48
24 Sep 21
Prospectus supplement
5:01pm
S-4/A
s7uq hz5kfifrfzw
8 Sep 21
Registration of securities issued in business combination transactions (amended)
2:59pm
424B3
k0pthf3q
23 Sep 21
Prospectus supplement
4:36pm
S-4
des0 vyrq
17 Aug 21
Registration of securities issued in business combination transactions
6:08am
424B4
2j2zlmrzhz
12 Jan 21
Prospectus supplement with pricing info
4:05pm
S-1
oryqpa386hti27g
7 Dec 20
IPO registration
5:02pm